State Street
MGX icon

State Street’s Metagenomi Therapeutics MGX Stock Holding History

State Street’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161K Hold
120,427
– – ﹤0.01% 3941
2025
Q4 		$195K Sell
120,427
-1,110
-0.9% -$2.4K ﹤0.01% 3907
2025
Q3 		$288K Sell
121,537
-9,273
-7% -$18.8K ﹤0.01% 3804
2025
Q2 		$194K Sell
130,810
-436,117
-77% -$683K ﹤0.01% 3846
2025
Q1 		$771K Buy
566,927
+137,023
+32% +$326K ﹤0.01% 3483
2024
Q4 		$1.55M Buy
429,904
+399,160
+1,298% +$963K ﹤0.01% 3389
2024
Q3 		$66.7K Buy
30,744
+270
+0.9% +$937 ﹤0.01% 4052
2024
Q2 		$124K Buy
+30,474
New +$209K ﹤0.01% 3946

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street's MGX Position: Q1 2026 in Review

State Street held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 120,427 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #3941.

State Street first reported a position in MGX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.55M in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • State Street held 120,427 shares of Metagenomi Therapeutics worth $161K as of Q1 2026.
  • State Street left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3941 holding.
  • State Street first reported a position in Metagenomi Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • State Street's Metagenomi Therapeutics position peaked at $1.55M in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.